duvelisib - Profile

What are the generic sources for duvelisib and what is the scope of patent protection?

Duvelisib is the generic ingredient in one branded drug marketed by Secura and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Duvelisib has two hundred and twenty-nine patent family members in thirty-nine countries.

Summary for duvelisib

International Patents:	229
US Patents:	6
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for duvelisib

Constraining patent/regulatory exclusivity:

RE46621

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for duvelisib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-001	Sep 24, 2018		RX	Yes	No	9,840,505
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-001	Sep 24, 2018		RX	Yes	No	9,216,982
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-001	Sep 24, 2018		RX	Yes	No	12,213,983
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-001	Sep 24, 2018		RX	Yes	No	11,312,718		Y
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-001	Sep 24, 2018		RX	Yes	No	RE46621		Y	Y

EU/EMA Drug Approvals for duvelisib

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Secura Bio Limited	Copiktra	duvelisib	EMEA/H/C/005381Copiktra monotherapy is indicated for the treatment of adult patients with: Relapsed or refractory chronic lymphocytic leukaemia (CLL) after at least two prior therapies. Follicular lymphoma (FL) that is refractory to at least two prior  systemic therapies.	Authorised	no	no	no	2021-05-19

International Patents for duvelisib

Country	Patent Number	Title	Estimated Expiration
South Africa	201005391	CERTAIN CHEMICAL ENTITIES,COMPOSITIONS AND METHODS
Japan	5868596
Australia	2013337717
Taiwan	I546305
Cyprus	2021035

Supplementary Protection Certificates for duvelisib

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2456444	LUC00237	Luxembourg		PRODUCT NAME: DUVELISIB; AUTHORISATION NUMBER AND DATE: EU1/21/1542 20210521
2914296	PA2021527	Lithuania		PRODUCT NAME: DUVELISIBAS; REGISTRATION NO/DATE: EU/1/21/1542 20210519
2456444	132021000000173	Italy		PRODUCT NAME: DUVELISIB(COPIKTRA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/21/1542, 20210521
2914296	LUC00238	Luxembourg		PRODUCT NAME: DUVELISIB; AUTHORISATION NUMBER AND DATE: EU/1/21/1542 20210521
2456444	CA 2021 00045	Denmark		PRODUCT NAME: DUVELISIB; REG. NO/DATE: EU/1/21/1542 20210521

Duvelisib: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Executive Summary

Duvelisib (brand name: Copiktra), developed by Verastem Oncology, is an oral phosphoinositide 3-kinase (PI3K) delta and gamma inhibitor approved for specific hematological malignancies, including chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), and relapsed/refractory follicular lymphoma (FL). Its niche positioning within aggressive cancer therapies creates unique market opportunities, but also faces significant competitive, regulatory, and market access challenges.

This analysis offers a comprehensive evaluation of duvelisib's investment prospects, reviewing market potential, competitive landscape, regulatory pathways, financial performance, and future implications.

---

1. Market Overview and Key Drivers

Parameter	Details
Indications	- Chronic lymphocytic leukemia (CLL) with or without 17p deletion - Relapsed/refractory follicular lymphoma (r/r FL) - Non-Hodgkin lymphoma (NHL) indications considered off-label or during trials
Market Size (2023)	- Global hematological malignancies market: ~$10B - Target segment (CLL/SLL and FL): approx. $5B, expected CAGR 8-10% (2023–2028)
Growth Drivers	- Increasing prevalence of CLL and NHL - Advantaging oral administration over infusion therapies - Unmet needs in refractory/relapsed cases - Advancements in targeted therapies

Regulatory approvals:

• FDA (2018): Approved duvelisib for CLL and SLL after prior therapy.
• EMA (European Medicines Agency): Approved for similar indications, limited by ongoing safety review.

Market dynamics:

• Oncologists favor targeted agents like BTK inhibitors (ibrutinib, acalabrutinib) and PI3K inhibitors (idelalisib) over chemotherapy.
• Competition mainly from other PI3K inhibitors (e.g., copanlisib), BTK inhibitors, and emerging CAR-T therapies.

---

2. Investment Scenario: Opportunities and Risks

2.1 Opportunities

Factor	Impact on Investment	Details
Untapped Residual Market Potential	High	Small patient populations for aggressive FDA-approved indications leave room for expansion through label expansion and off-label uses.
Combination Therapy Potential	Significant	Early trials suggest that duvelisib combined with other agents may enhance efficacy, broadening its commercial horizon.
Pricing and Reimbursement	Moderate to High	Oral targeted agents command premium pricing; ongoing negotiations with payers favor accessible pricing strategies.
FDA and EMA Approvals Extension	Positive	Additional approvals for earlier-line therapy or other hematologists’ indications can substantially boost sales.

2.2 Risks

Factor	Impact on Investment	Details
Safety and Tolerability Concerns	Critical	Adverse events (AEs) such as hepatotoxicity, colitis, infections—prompt regulatory scrutiny and potential label restrictions.
Competitive Landscape	Intense	Dominance of BTK inhibitors (e.g., ibrutinib), idelalisib, and emerging therapies like CAR-T reduces duvelisib's market share.
Regulatory Challenges	Significant	Post-marketing safety data could lead to restrictions or withdrawal.
Limited Global Access	Restricts Growth	Market penetrations vary by region; access to approval in emerging markets is uncertain.

---

3. Market Dynamics and Competitive Landscape

3.1 Competitive Positioning

Agent/Table	Mechanism	Indications	Market Share (2023)	Key Strengths/Weaknesses
Duvelisib (Copiktra)	PI3K delta/gamma inhibitor	CLL, SLL, FL	~5-8% (estimated)	Oral, convenience, safety concerns
Idelalisib (Zydelig)	PI3K delta inhibitor	CLL, follicular lymphoma	~10%	Established, early approvals, safety issues
Ibrutinib (Imbruvica)	BTK inhibitor	CLL, NHL	>50%	Market leader, broad indications, off-label expansion
Acalabrutinib (Calquence)	BTK inhibitor	CLL	~15%	Favorable safety profile
Copanlisib (Aliqqua)	PI3K alpha/delta inhibitor	NHL	3-4%	Intravenous, niche indication

Note: Precise market shares are estimated based on clinical adoption trends, sales data, and recent industry reports (e.g., EvaluatePharma, IQVIA, 2022-2023 projections).

3.2 Regulatory and Reimbursement Considerations

Region	Status	Notes
US (FDA)	Approved for specific hematologic malignancies	Post-marketing safety review ongoing
EU (EMA)	Approved; safety warnings issued	Restrictions on certain indications or usage
APAC, LATAM, MEA	Limited access; regulatory approvals pending or under review	Market entry contingent upon local assessments

---

4. Financial Trajectory & Revenue Projections

Parameter	2023	2024	2025	CAGR (2023–2025)
Estimated Revenue	~$50–70M	~$100–150M	~$200–300M	~65%
Key Assumptions	Market growth 8–10%, new indications, successful label expansion	Launch of potential combinations, expanded approvals	Geographic penetration, patient treatment persistence

Note: Verastem's financials indicate modest revenues, with a focus on clinical development and submission pipelines. The trajectory hinges on regulatory successes, safety profile, and competitive positioning.

---

5. Regulatory and Policy Environment

• FDA’s Oncology Drug Policies: Increasing focus on safety and efficacy; expedited pathways (e.g., Breakthrough Therapy) could accelerate approvals.

• EMA's Post-Approval Safety Monitoring: Enhanced vigilance for adverse effects. Regulatory restrictions may influence sales.

• Market Access Policies: Reimbursement frameworks vary, impacting net sales. Payers favor cost-effective, well-tolerated therapies.

---

6. Comparative Analysis: Duvelisib vs. Similar Drugs

Attribute	Duvelisib	Idelalisib	Ibrutinib	Acalabrutinib
Mechanism	Dual PI3K delta/gamma	PI3K delta	BTK inhibition	BTK inhibition
FDA Approval Year	2018	2014	2013	2019
Indications (Current)	CLL/SLL, FL	CLL, follicular lymphoma	CLL, WM, MCL, others	CLL, MCL
Market Share (2023)	~5–8%	~10%	>50%	~15%
Safety Concerns	Yes	Yes	Moderate	Less

---

7. Future Outlook and Potential Investment Strategies

• Diversification into Combination Therapies: Clinical trials combining duvelisib with monoclonal antibodies or chemoimmunotherapy could extend lifecycle and improve efficacy.

• Expanding Indications: Pursuing label extensions for earlier lines of therapy or additional lymphoma subtypes threatens increased competition but widens revenue streams.

• New Market Entry and Geography Expansion: Key to growth is navigating regulatory pathways in emerging regions; partnerships or licensing deals may accelerate access.

• Monitoring Safety Profile: Adverse events must be managed carefully to sustain regulatory approval and payer confidence.

---

8. Key Takeaways

Insights	Actionable Recommendations
Market leadership is challenged by existing BTK inhibitors	Focus on niche indications, combination therapies, and safety improvements
Safety concerns significantly impact sales potential	Invest in post-market safety management and real-world evidence collection
Regulatory landscape is evolving with increased scrutiny	Maintain proactive engagement with regulators; prepare comprehensive safety data
Market expansion opportunities exist via label extensions and regional approvals	Prioritize strategic regulatory applications in underserved geographies
Competitive advantage hinges on unique positioning and tolerability	Leverage clinical trial data and real-world outcomes to support brand differentiation

---

9. FAQs

Q1: What is the primary therapeutic advantage of duvelisib over other PI3K inhibitors?
A: Duvelisib uniquely inhibits both delta and gamma isoforms of PI3K, potentially offering broader immunomodulatory effects. However, this dual action requires careful safety profiling.

Q2: How does duvelisib's safety profile impact its market potential?
A: Significant adverse events, such as hepatotoxicity and infections, necessitate vigilant management and may limit off-label use, impacting sales and market expansion.

Q3: What are the key regulatory hurdles for duvelisib’s future growth?
A: Ongoing safety reviews and potential labeling restrictions by FDA/EMA pose challenges; successful labeling extensions depend on favorable safety data.

Q4: What competitors are most likely to threaten duvelisib's market share?
A: Dominant BTK inhibitors like ibrutinib and acalabrutinib, along with other PI3K agents like copanlisib, are primary competitors due to established efficacy and safety profiles.

Q5: What strategies should investors consider for duvelisib?
A: Focus on pipeline development, strategic labeling extensions, geographic expansion, and safety profile improvements to maximize long-term value.

---

References

[1] Verastem Oncology. Copiktra (duvelisib) prescribing information. 2018.
[2] EvaluatePharma. Oncology Market Report 2022–2023.
[3] IQVIA. Hematologic Malignancies Sales Data, 2022.
[4] European Medicines Agency. Safety updates on PI3K inhibitors, 2022.
[5] Market Research Future. Hematology Drugs Market Size & Trends, 2023.

---

Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. Investors should conduct thorough due diligence and consult with financial advisors before making investment decisions related to duvelisib or related assets.